IL6R

4 papers3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

A gene’s or a process’s line counts the gene with the processes named after it, as NLRP3 with the NLRP3 inflammasome, and the trials of drugs aimed at it.

1 lab in 1 country

Funders: Agency for Healthcare Research and Quality and others

Humans2
Animals1

Effects

C-reactive protein

downin humans1

1 study

IL6R decreases C-reactive protein in humans (-8.35%, 95% CI 7.31-9.38).
“reduced C-reactive protein (decrease per allele 8·35%, 95% CI 7·31-9·38)”
Humansper allele
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Lancet (London, England)14 Mar 2012

Associations

Coronary heart disease

downin humans1OR 0.95

1 study

IL6R lowers the risk of coronary heart disease in humans (OR 0.95, 95% CI 0.93-0.97, p=1.53x10(-5)).
“In 25,458 coronary heart disease cases and 100,740 controls, the IL6R rs7529229 SNP was associated with a decreased odds of coronary heart disease events”
Humansper allele
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Lancet (London, England)14 Mar 2012